0000315066-18-000120.txt : 20180131
0000315066-18-000120.hdr.sgml : 20180131
20180131164347
ACCESSION NUMBER: 0000315066-18-000120
CONFORMED SUBMISSION TYPE: SC 13G
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20180131
DATE AS OF CHANGE: 20180131
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: Menlo Therapeutics, Inc.
CENTRAL INDEX KEY: 0001566044
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 453757789
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: SC 13G
SEC ACT: 1934 Act
SEC FILE NUMBER: 005-90268
FILM NUMBER: 18563340
BUSINESS ADDRESS:
STREET 1: 4085 CAMPBELL AVENUE, SUITE 200
CITY: MENLO PARK
STATE: CA
ZIP: 94025
BUSINESS PHONE: 650-486-1416
MAIL ADDRESS:
STREET 1: 4085 CAMPBELL AVENUE, SUITE 200
CITY: MENLO PARK
STATE: CA
ZIP: 94025
FORMER COMPANY:
FORMER CONFORMED NAME: Tigercat Pharma, Inc.
DATE OF NAME CHANGE: 20130104
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: FMR LLC
CENTRAL INDEX KEY: 0000315066
STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000]
IRS NUMBER: 043532603
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: SC 13G
BUSINESS ADDRESS:
STREET 1: 245 SUMMER STREET
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6175706339
MAIL ADDRESS:
STREET 1: 245 SUMMER STREET
CITY: BOSTON
STATE: MA
ZIP: 02210
FORMER COMPANY:
FORMER CONFORMED NAME: FMR CORP
DATE OF NAME CHANGE: 19920717
SC 13G
1
filing.txt
SCHEDULE 13G
Amendment No. 0
MENLO THERAPEUTICS INC
COMMON STOCK
Cusip #586858102
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
[ ] Rule 13d-1(b)
[x] Rule 13d-1(c)
[ ] Rule 13d-1(d)
Cusip #586858102
Item 1: Reporting Person - FMR LLC
Item 2: (a) [ ]
(b) [ ]
Item 4: Delaware
Item 5: 1,094,207
Item 6: 0
Item 7: 1,118,054
Item 8: 0
Item 9: 1,118,054
Item 11: 5.098%
Item 12: HC
Cusip #586858102
Item 1: Reporting Person - Abigail P. Johnson
Item 2: (a) [ ]
(b) [ ]
Item 4: United States of America
Item 5: 0
Item 6: 0
Item 7: 1,118,054
Item 8: 0
Item 9: 1,118,054
Item 11: 5.098%
Item 12: IN
Item 1(a). Name of Issuer:
MENLO THERAPEUTICS INC
Item 1(b). Address of Issuer's Principal Executive Offices:
4085 CAMPBELL AVENUE, SUITE 200
MENLO PARK, CA 94025
US
Item 2(a). Name of Person Filing:
FMR LLC
Item 2(b). Address or Principal Business Office or, if None,
Residence:
245 Summer Street, Boston, Massachusetts 02210
Item 2(c). Citizenship:
Not applicable
Item 2(d). Title of Class of Securities:
COMMON STOCK
Item 2(e). CUSIP Number:
586858102
Item 3. Not Applicable
Item 4. Ownership
(a) Amount Beneficially Owned: 1,118,054
(b) Percent of Class: 5.098%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote:
1,094,207
(ii) shared power to vote or to direct the vote: 0
(iii) sole power to dispose or to direct the
disposition of: 1,118,054
(iv) shared power to dispose or to direct the
disposition of: 0
Item 5. Ownership of Five Percent or Less of a Class.
Not applicable.
Item 6. Ownership of More than Five Percent on Behalf of Another
Person.
One or more other persons are known to have the right to receive or the
power to direct the receipt of dividends from, or the proceeds from the
sale of, the COMMON STOCK of MENLO THERAPEUTICS INC. The interest of
F-Prime Capital Partners Healthcare Fund IV LP, in the COMMON STOCK of
MENLO THERAPEUTICS INC., amounted to 1,118,054 shares or 5.098% of the
total outstanding COMMON STOCK at January 29, 2018.
Item 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on By the Parent Holding Company.
See attached Exhibit A.
Item 8. Identification and Classification of Members of the Group.
Not applicable.
Item 9. Notice of Dissolution of Group.
Not applicable.
Item 10. Certifications.
By signing below I certify that, to the best of my knowledge and belief,
the securities referred to above were not acquired and are not held for the
purpose of or with the effect of changing or influencing the control of the
issuer of the securities and were not acquired and are not held in
connection with or as a participant in any transaction having that purpose
or effect.
Signature
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete
and correct.
January 30, 2018
Date
/s/ Marc R. Bryant
Signature
Marc R. Bryant
Duly authorized under Power of Attorney effective as of September 23,
2015, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
* This power of attorney is incorporated herein by reference to Exhibit 24
to the Schedule 13G filed by FMR LLC on June 10, 2016, accession number:
0000315066-16-005935
Exhibit A
Pursuant to the instructions in Item 7 of Schedule 13G,
the following table lists the identity and Item 3 classification, if
applicable, of each relevant entity that beneficially owns shares of the
security class being reported on this Schedule 13G.
Entity ITEM 3 Classification
IMPRESA MANAGEMENT LLC * IA
* Entity beneficially owns 5% or greater of the outstanding shares of the
security class being reported on this Schedule 13G.
Abigail P. Johnson is a Director, the Chairman and the
Chief Executive Officer of FMR LLC.
Members of the Johnson family, including Abigail P.
Johnson, are the predominant owners, directly or through trusts, of Series
B voting common shares of FMR LLC, representing 49% of the voting power of
FMR LLC. The Johnson family group and all other Series B shareholders have
entered into a shareholders' voting agreement under which all Series B
voting common shares will be voted in accordance with the majority vote of
Series B voting common shares. Accordingly, through their ownership of
voting common shares and the execution of the shareholders' voting
agreement, members of the Johnson family may be deemed, under the
Investment Company Act of 1940, to form a controlling group with respect to
FMR LLC.
This filing reflects the securities beneficially owned, or
that may be deemed to be beneficially owned, by FMR LLC, certain of its
subsidiaries and affiliates, and other companies (collectively, the "FMR
Reporters"). This filing does not reflect securities, if any, beneficially
owned by certain other companies whose beneficial ownership of securities
is disaggregated from that of the FMR Reporters in accordance with
Securities and Exchange Commission Release No. 34-39538 (January 12, 1998).
RULE 13d-1(k)(1) AGREEMENT
The undersigned persons, on January 30, 2018, agree and
consent to the joint filing on their behalf of this Schedule 13G in
connection with their beneficial ownership of the COMMON STOCK of MENLO
THERAPEUTICS INC at January 25, 2018.
FMR LLC
By /s/ Marc R. Bryant
Marc R. Bryant
Duly authorized under Power of Attorney effective as of September 23,
2015, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Abigail P. Johnson
By /s/ Marc R. Bryant
Marc R. Bryant
Duly authorized under Power of Attorney effective as of December 16,
2015, by and on behalf of Abigail P. Johnson*
* This power of attorney is incorporated herein by reference to Exhibit 24
to the Schedule 13G filed by FMR LLC on June 10, 2016, accession number:
0000315066-16-005935